TP53 and cancer: Given that ING1 is down-regulated in many human malignancies [2], [3], this model implies ING1 as a prognostic factor for response to targeted cancer therapy: patients with tumors expressing low ING1-levels might not significantly profit from certain proteasome-inhibitors or other anticancer agents, that involve the induction of p53-dependent apoptosis in the selective killing of tumor cells.